How India Exports Sofosbuvir to the World

In the United States, sofosbuvir received its initial approval from the Food and Drug Administration (FDA) in December 2013 under the brand name Sovaldi. Subsequent approvals include combination therapies such as Harvoni (ledipasvir/sofosbuvir) in October 2014 and Epclusa (sofosbuvir/velpatasvir) in June 2016. These approvals have facilitated the entry of generic versions into the market. According to the FDA's Orange Book, multiple Abbreviated New Drug Applications (ANDAs) for sofosbuvir have been approved, indicating a competitive generic landscape. Notably, Indian pharmaceutical companies have been active in this domain, with 150 exporters contributing to the global distribution of sofosbuvir. The regulatory pathway for sofosbuvir in the U.S. involves rigorous evaluation of bioequivalence and manufacturing standards to ensure safety and efficacy.

The European Medicines Agency (EMA) granted marketing authorization for Sovaldi (sofosbuvir) on January 16, 2014, for use in combination with other medicinal products for the treatment of chronic hepatitis C in adults and pediatric patients aged 3 years and above. (ema.europa.eu) Subsequent approvals include combination therapies such as Epclusa (sofosbuvir/velpatasvir) in July 2016 and Vosevi (sofosbuvir/velpatasvir/voxilaprevir) in July 2017. (ema.europa.eu) The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has aligned with EMA's decisions, ensuring consistent regulatory standards across Europe. Compliance with Good Manufacturing Practice (GMP) requirements is mandatory for manufacturers, ensuring product quality and patient safety.

Sofosbuvir is included in the World Health Organization's (WHO) Model List of Essential Medicines, reflecting its critical role in public health. The WHO Prequalification Programme has assessed and prequalified certain sofosbuvir products, facilitating their procurement by UN agencies and member states. Pharmacopoeial standards for sofosbuvir are outlined in major compendia, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring consistent quality benchmarks globally.

In India, sofosbuvir is classified under Schedule H1 of the Drugs and Cosmetics Rules, 1945, indicating that it is a prescription drug subject to specific regulatory controls. The National Pharmaceutical Pricing Authority (NPPA) has set ceiling prices for sofosbuvir to ensure affordability; for instance, a price cap was established in March 2024. Export of sofosbuvir requires a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national regulations and monitoring of pharmaceutical exports.

The primary patent for sofosbuvir, held by Gilead Sciences, has expired in several jurisdictions, paving the way for generic competition. This has led to increased market participation by generic manufacturers, including those from India, thereby enhancing global access to this essential medication.

In June 2025, the NPPA revised the ceiling price for sofosbuvir, reducing it by 10% to enhance affordability. In September 2025, the EMA approved a new generic version of sofosbuvir, expanding treatment options within the European Union. In December 2025, the WHO updated its treatment guidelines for HCV, recommending sofosbuvir-based regimens as first-line therapy. In February 2026, the FDA issued a warning letter to a manufacturer for non-compliance with GMP standards in sofosbuvir production, highlighting the importance of stringent quality controls. In March 2026, the Indian government announced incentives for pharmaceutical companies to boost the production and export of generic sofosbuvir, aiming to strengthen India's position in the global pharmaceutical market.

These developments underscore the dynamic nature of the regulatory and market landscape for sofosbuvir, reflecting ongoing efforts to balance innovation, quality, and accessibility in the treatment of chronic hepatitis C.

India's pharmaceutical industry, including the production of sofosbuvir, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. Approximately 60–70% of these essential components are sourced from China, underscoring a significant dependency that poses risks to the supply chain. This reliance became particularly evident during the COVID-19 pandemic, when disruptions in Chinese manufacturing and logistics led to shortages and increased costs for Indian pharmaceutical companies.

In response to these vulnerabilities, the Indian government introduced the Production Linked Incentive (PLI) scheme in March 2020, aiming to bolster domestic production of critical APIs and KSMs. While this initiative has led to some progress, the transition to self-sufficiency is gradual, and the industry continues to depend on Chinese imports for a substantial portion of its raw materials.

Our proprietary trade data from 2022 to 2026 reveals a high supplier concentration in the export of sofosbuvir from India. The top five exporters account for 92.4% of the total export value, with MYLAN LABORATORIES LIMITED alone contributing 64.8% ($26.5 million USD). This significant concentration indicates a potential single-source risk, where disruptions affecting these key suppliers could have a pronounced impact on the global availability of sofosbuvir.

The PLI scheme, initiated in March 2020, aims to diversify and strengthen the pharmaceutical manufacturing base in India. However, as of March 2026, the scheme's impact on reducing supplier concentration in sofosbuvir exports appears limited, with the market still dominated by a few major players.

Recent geopolitical tensions have significantly disrupted global shipping routes critical to pharmaceutical supply chains. The closure of the Strait of Hormuz in early March 2026, following military escalations involving the United States, Israel, and Iran, has led to a near halt in maritime traffic through this vital corridor. This disruption has affected approximately 20% of the world's daily oil supply and significant volumes of liquefied natural gas (LNG), causing oil prices to surge and leading to broader economic repercussions.

Additionally, the Red Sea has become a hotspot for maritime security threats, with major shipping lines suspending transits due to attacks on merchant vessels. These disruptions have forced rerouting of shipments, increased transit times, and elevated shipping costs, further straining the pharmaceutical supply chain.

• Diversify API and KSM Sources: Encourage and invest in the development of alternative sources for APIs and KSMs, both domestically and from other countries, to reduce dependency on a single nation.

• Expand Supplier Base: Promote policies and incentives that support the growth of small and medium-sized pharmaceutical manufacturers to decrease market concentration and mitigate single-source risks.

• Enhance Supply Chain Resilience: Develop and implement robust contingency plans, including alternative shipping routes and strategic stockpiling, to address potential disruptions in critical maritime corridors.

• Strengthen Regulatory Frameworks: Collaborate with international regulatory bodies to ensure compliance and adaptability to changing geopolitical landscapes, facilitating smoother trade operations.

• Invest in Infrastructure: Allocate resources to improve domestic manufacturing capabilities and logistics infrastructure, reducing reliance on external factors and enhancing overall supply chain stability.

RISK_LEVEL: HIGH